Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report

Yosuke Shibata; Go Noguchi; Takahisa Suzuki; Kimito Osaka; Susumu Umemoto; Takeshi Kishida

doi:10.12659/AJCR.932924

06 August 2021 : Case report Japan

Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report

Unusual clinical course, Unusual or unexpected effect of treatment

Yosuke Shibata^1AEF*, Go Noguchi^1EF, Takahisa Suzuki^1E, Kimito Osaka^1E, Susumu Umemoto^1E, Takeshi Kishida^1EF

DOI: 10.12659/AJCR.932924

Am J Case Rep 2021; 22:e932924

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 1. The CT scan shows left adrenal and lung metastases before initial nivolumab therapy (A), after 3 cycles of nivolumab therapy (B), and 7 months after nivolumab discontinuation (C).

Back to the Article

Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report

Your Privacy